Diridavumab is a monoclonal anti-HA stalk antibody. Diridavumab stabilizes the prefusion HA structure and prevents pH-dependent fusion of cellular and viral membranes in endosomes. Diridavumab can be used in research of H2 influenza virus.
Diridavumab (CR6261; 500 μg/mL) neutralized AA60 and Sw06 with 39.4 μg/mL and 176.8μg/mL, respectively[1].
Diridavumab (CR6261; 1.7-15 mg/kg; i.p.; BALB/c mice with H2 influenza virus) protects mice against lethal H2 influenza virus in a dose-dependent manner[1].
References:
[1]. Sutton TC, et, al. In Vitro Neutralization Is Not Predictive of Prophylactic Efficacy of Broadly Neutralizing Monoclonal Antibodies CR6261 and CR9114 against Lethal H2 Influenza Virus Challenge in Mice. J Virol. 2017 Nov 30;91(24):e01603-17.